Thursday, January 01, 2026 1:26:29 PM
I want to counter Brazen's post which mostly put all the blame on the time it's taken to bring DCVax to commercialization smack on the company. There are several reasons why it's taken a long time, and bashers posting outright lies and cutting down the company with no facts - or facts they've helped create - are very, very much a part of the problem. Greed is behind all the bashing, whether it be individual swing-traders, BP trying to get rid of or control the competition, or billionaires who discounted NWBO's CEO's tenacity and DCVax's ability to cure or stave off death in patients, and shorted the stock to the tune of millions over the past 10 years. These people helped bring down our share price from a high of $12.55 to as low as 14 cents. NWBO has sued 7 Market Makers for spoofing, a way of controlling share prices, and are doing well with the court case. So I have to believe there is some truth to the company's claim that their share price is being manipulated.
And let's be real: A 23 cent share has tremendously less buying power than a $12.55 share or, for that matter, the $6 shares that most of us early investors paid in 2013 and 2014. Think for a moment where our share price and our number of shares would be without 10 years of greedy manipulation, much of it by millionaires and billionaires.Think of where our commercialization efforts would be.
But there were certainly other issues. One of them is simply that Dr. Liau, Dr. Bosch and the NWBO team were well ahead of regulators in preparing for the futuristic nature of DCVax-L. As I've often said here on iHub, NWBO had to improve, recreate, discover, or invent most of the technology needed to truly commercialize DCVax. How did regulators spend those 10 years? Approving cancer "improvements" that were lucky if they gave patients even just two more months of life? But hey, patients got hope and other people got rich, right?
Despite the 2015 Phase 5 attack piece that started this 10-year attack on NWBO, Dr. Liau's team at UCLA and NWBO's Dr. Marnix Bosch's continued development of DCVax and invention of Direct have made DCVax so much more of a cure for patients. Add Linda Powers' hard work at bringing inventors (think Flaskworks investors and Dr. Kalinski's life's work) into the fold, and here we are today, infinitely closer to a real "cure" for many patients, and at the door of turning cancer from a death sentence into a manageable disease.
Within a month, we should have our first approval for DCVax from the UK, IMO. And many more lives will be saved. (I say this as a fact because we have seen these survivors and heard the numbers.)
Yet the bashers are still here, posting their silly comments, desperately trying to keep the price below 25 cents.
Why are they still here?
I think all longs know the answer.
It's greed.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
